Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada

OBJECTIVE: To assess outcomes over 24 months in Canadian patients with schizophrenia initiated on risperidone long-acting injection (RLAI) and participating in the electronic Schizophrenia Treatment Adherence Registry (e-STAR). MATERIALS AND METHODS: Patients with schizophrenia or schizoaffective di...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Richard, Chandrasena, Ranjith, Beauclair, Linda, Luong, Doanh, Lam, Annette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942298/
https://www.ncbi.nlm.nih.gov/pubmed/24600227
http://dx.doi.org/10.2147/NDT.S54740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942298/
https://www.ncbi.nlm.nih.gov/pubmed/24600227
http://dx.doi.org/10.2147/NDT.S54740

Ejemplares similares